<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="209">
  <!-- This xml conforms to:  http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>Information obtained from ClinicalTrials.gov on October 20, 2011</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01169935</url>
  </required_header>
  <id_info>
    <org_study_id>10/S1102/31</org_study_id>
    <nct_id>NCT01169935</nct_id>
  </id_info>
  <brief_title>Tracking Inflammatory Cells Using Superparamagnetic Particles of Iron Oxide (SPIO) and Magnetic Resonance Imaging (MRI)</brief_title>
  <official_title>In Vivo Tracking of Magnetically-labelled Human Mononuclear Cells Using MRI Scanning</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Edinburgh</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Translational Medicine Research Collaboration</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>British Heart Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Edinburgh</source>
  <oversight_info>
    <authority>United Kingdom: Research Ethics Committee</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Treatment of a wide range of diseases using stem cells and other types of cell appears
      promising. Following administration of cells it is often not clear where exactly the cells
      have gone and how many of them have reached the target site. This has been one of the
      challenges of developing these treatment options further. We have developed a method of
      labelling human cells with a magnetic resonance imaging (MRI) &quot;contrast agent&quot; which
      contains tiny iron filings. Following intravenous administration it is possible to see where
      the iron-labelled cells have gone using MRI scanning. We would like to do is to demonstrate
      that these cells behave normally and migrate to a site of inflammation. We plan to induce an
      area of inflammation in the forearm of healthy volunteers using the Mantoux test (a test of
      immunity against tuberculosis) before giving the labelled cells intravenously. After the
      Mantoux test we will give these volunteers iron-labelled cells and do MRI scans of their
      forearm to determine whether these cells can be seen accumulating in the target site.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>July 2010</start_date>
  <primary_completion_date type="Anticipated">June 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation:  Non-Randomized, Intervention Model:  Parallel Assignment, Masking:  Open Label, Primary Purpose:  Diagnostic</study_design>
  <primary_outcome>
    <measure>Change in signal intensity in the region of interest on MRI scanning</measure>
    <time_frame>0 hours, 24 hours, 48 hours, 3 - 5 days</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">38</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Administration of Intra-dermal SPIO</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MRI scanning before and after intra-dermal injection of SPIO.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Mantoux, Venesection, Labelled cells</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Mantoux test then MRI scanning before and after administration of iron-labelled cells obtained by venesection.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Mantoux, Apheresis, Labelled cells</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Mantoux test then MRI scanning before and after administration of iron-labelled cells obtained by apheresis.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Mantoux, Administration of Endorem</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Mantoux test then MRI scanning before and after administration of Endorem.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Mantoux only</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Mantoux test then serial MRI scanning.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Administration of intra-dermal Endorem</intervention_name>
    <description>single dose, intradermal</description>
    <arm_group_label>Administration of Intra-dermal SPIO</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Mantoux test</intervention_name>
    <description>single dose, intradermal</description>
    <arm_group_label>Mantoux, Venesection, Labelled cells</arm_group_label>
    <arm_group_label>Mantoux, Apheresis, Labelled cells</arm_group_label>
    <arm_group_label>Mantoux, Administration of Endorem</arm_group_label>
    <arm_group_label>Mantoux only</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Autologous Endorem-labelled mononuclear cells</intervention_name>
    <description>single dose, intravenous</description>
    <arm_group_label>Mantoux, Venesection, Labelled cells</arm_group_label>
    <arm_group_label>Mantoux, Apheresis, Labelled cells</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Administration of Endorem</intervention_name>
    <description>single dose, intravenous</description>
    <arm_group_label>Mantoux, Administration of Endorem</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy male or female volunteers age 18 to 65 years

          -  Previous vaccine for tuberculosis more than 5 years ago

        Exclusion Criteria:

          -  pregnancy / breast feeding

          -  Contra-indication to MRI scanning

          -  Inability or refusal to give informed consent

          -  Renal failure (eGFR &lt;25mL/min) or hepatic dysfunction (Child's B or C)

          -  HIV/hepatitis B/hepatitis C/HTLV/syphilis

          -  Active malignant disease

          -  Anaemia

          -  Blood dyscrasia

          -  High risk of allergy to protamine sulphate (fish allergy, infertile men, vasectomy)

          -  Known history of tuberculosis infection.

          -  History of prolonged residence (&gt; 6 months) in a region or country with a high
             prevalence of tuberculosis.

          -  Previous Mantoux reaction of 15mm of greater.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jenny M Richards, MBChB MRCS</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Edinburgh</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Michelle C Williams, MBChB MRCP</last_name>
    <phone>01312426379</phone>
    <email>michelle.williams@ed.ac.uk</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Edinburgh / Royal Infirmary of Edinburgh</name>
      <address>
        <city>Edinburgh</city>
        <state>Scotland</state>
        <zip>EH16SU4</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>July 2010</verification_date>
  <lastchanged_date>July 23, 2010</lastchanged_date>
  <firstreceived_date>July 23, 2010</firstreceived_date>
  <responsible_party>
    <name_title>Professor David Newby</name_title>
    <organization>University of Edinburgh</organization>
  </responsible_party>
  <keyword>MRI</keyword>
  <keyword>SPIO</keyword>
  <keyword>Healthy Volunteer</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
</clinical_study>
